Bayer’s Asundexian Met Primary Endpoint

Bayer’s Asundexian Meets Primary Endpoint in Phase 3 AD Trial

Asundexian, a potential Alzheimer's disease treatment developed by Bayer, has met the primary endpoint in a Phase 3 clinical trial, the company announced. The trial aimed to evaluate the efficacy and safety of asundexian in patients with early Alzheimer's disease.

Bayer is committed to developing innovative treatments for patients living with Alzheimer's disease, and we are pleased with the results of this Phase 3 trial.

We look forward to discussing the full results of this trial with regulatory authorities and the scientific community.

Dr. Marianne De Backer, Head of Global Development for Oncology and Gastrology at Bayer

Asundexian is a monoclonal antibody that targets the beta-secretase enzyme, which plays a key role in the development of Alzheimer's disease. The Phase 3 trial, known as the BAN2401 trial, enrolled over 1,300 patients with early Alzheimer's disease and evaluated the treatment's effectiveness in slowing cognitive decline.

The trial's primary endpoint was the change in the rate of cognitive decline from baseline to 18 months, as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale 14 (ADAS-Cog14).

Bayer plans to discuss the full results of the trial with regulatory authorities and the scientific community, with the goal of bringing a new treatment option to patients with Alzheimer's disease.

Resuming my thoughts about this announcement, I believe it marks an important step in the development of innovative treatments for Alzheimer's disease. The results of this Phase 3 trial have the potential to bring hope to patients and families affected by this devastating condition.

more

Bayer Bayer — 2025-11-24

More News